Recent studies have converged on the overlap of GLP|GIP|glucagon receptor agonist therapies and dopamine communication. While GIP stimulators are increasingly employed for managing type 2 diabetes mellitus, their emerging impacts on motivation circuits, specifically governed by dopamine systems,